The diffi culty of designing new analgesic drugs is evident in the biochemical maze that results when an opioid agonist binds to opioid receptors, triggering a complex cascade of intracellular mechanisms. In an effort to enhance understanding of the biochemical and pharmacological mechanisms that are responsible for the action of opioid drugs, we describe the characterization of the zebrafi sh opioid system, a novel experimental approach to unravel the molecular mechanisms that underlie opioid activity. We have cloned the zebrafi sh opioid receptors and peptides, established their expression pattern during development and in the adult organism, and determined their pharmacological profi les and biochemical properties. Furthermore, developmental studies in the zebrafi sh yield valuable information about the developmental roles of the opioid receptors. Building on these fi ndings, we show that the zebrafi sh opioid receptors and peptides present molecular, pharmacological, and biochemical profi les that are fundamentally similar to those of their mammalian counterparts and from which results can therefore be extrapolated to higher vertebrates. Thus the zebrafi sh represents a straightforward model to study opioid activity, and can be very useful not only for the analysis of the complex endogenous systems that regulate the action of opioid agents but also for in vivo tests of novel analgesic drugs. 
The Zebrafi sh: A Model to Study the Endogenous Mechanisms of Pain or the development of potential novel therapeutic approaches, good animal models should reproduce several physiological or clinical features and fulfi ll a number of requirements that ensure their effectiveness and utility (e.g., clinical relevance, reproducibility, and quantifi cation). In addition, there must be a correlation among the behavioral, biochemical, physiological, and structural traits in the chosen animal model, so it is essential to begin by assessing and validating the experimental model itself. Finally, the model must address ethical considerations (e.g., through the justifi cation for the protocol, application of noninvasive procedures, and use of the minimum number of animals needed), which are especially important in studies of pain and analgesia as these almost always require the use of a painful stimulus and in some cases involve a high degree of animal suffering. The most commonly used animal models are rodents, such as the rat and mouse, but certain studies require the use of animals that are phylogenetically closer to humans (such as primates), increasing the costs and the length of the trial. Such studies also raise ethical concerns among members of both the scientifi c community and society at large.
When the main aim of a study is to identify the genes involved in the embryonic development of body structures or to establish the genetic causes of a disease, a straightforward approach is to work with the simplest model possible and then add increasing degrees of complexity. The selection of animal model depends on the parameters of the study and practical considerations. For example, a study of developmental processes that are present only in vertebrates (e.g., the development of the central nervous system, neural crests, or circulatory system) rules out the use of invertebrates such as Caenorhabditis elegans or Drosophila. Models such as the amphibian Xenopus laevis or the chicken typically have long generation times and entail greater space requirements, and with mice there are drawbacks such as intrauterine development and the low number of offspring.
The Zebrafi sh: A Novel Experimental Model
The teleost zebrafi sh (Danio rerio) has recently joined the repertoire of model organisms used in developmental studies, together with the mouse (Mus musculus), chicken (Gallus gallus), frog (X. laevis), fruit fl y (Drosophila melanogaster), and nematode (C. elegans). The main advantages of the zebrafi sh are its small size (which makes it possible to maintain many individuals and to preserve different mutant lines in a reduced space), its short generation time (about 3 months), the large number of offspring (hundreds of eggs per female), and the external development of transparent eggs. Furthermore, the development of the zebrafi sh is fast-at 24 hours postfertilization (hpf 1 ) it is possible to distinguish structures such as the notochord, the main brain divisions, the heart, and the eyes, and at 3 days postfertilization embryonic development is complete. In addition, this organism enables in vivo analysis of the development of many vertebrate features, such as the excretory system, heart, hematopoiesis, notochord, neural tube, and neural crests (Dooley and Zon 2000) . Last, using microinjection techniques it is possible to generate transgenic fi sh or to manipulate single cells, track them during development, or transplant them (Detrich et al. 1999) .
Recent studies indicate that the zebrafi sh is a suitable model to analyze the biochemical basis of certain human diseases, such as hematopoietic disorders, cardiovascular abnormalities, kidney malfunction, and some types of deafness (reviewed in Ackermann and Paw 2003; Dooley and Zon 2000; Lieschke and Currie 2007; Shin and Fishman 2003) , or even more complex pathologies such as cancer (Stoletov and Klemke 2008) . Other studies have used the zebrafi sh as a model organism for the discovery and validation of novel drug targets and therapeutic agents as well as for toxicological analysis (Goldsmith 2004) .
The possibility of high-throughput phenotyping has also made the zebrafi sh one of the most popular organisms for large-scale drug discovery and chemical genomics (reviewed in Goldsmith 2004; den Hertog 2005; Langheinrich 2003; Love et al. 2004; Pichler et al. 2003; Zon and Peterson 2005) . A phenotype-based screen can be combined with the use of a transgenic line to label specifi c cells in vivo. Perhaps even more signifi cant from a pharmaceutical perspective is the fact that small-molecule screens enable the identifi cation of compounds that suppress defects due to mutations in specifi c genes, as in the case of the chemical suppression of the gridlock mutation (Peterson et al. 2004 ). Because of its ability to incorporate water-soluble molecules, the zebrafi sh can also be used to study interactions between the genome and the environment (Fishman 2001) .
Widespread acceptance of the zebrafi sh as a novel experimental model will require the establishment of a set of quantitative behavioral tests. To that end, a recent issue of the journal Zebrafi sh was dedicated to the latest fi ndings in zebrafi sh behavior and reports of available behavioral tests (Bally-Cuif 2006) . A study by Lockwood and colleagues (2004) focused on the effects of chronic ethanol treatment on the locomotor activity and place preference of zebrafi sh larvae; their results indicate that locomotive disorders such as hyperactivity are equivalent between zebrafi sh larvae and humans, and that these disorders are genetically determined. And experiments using the conditioned place preference (CPP) paradigm have yielded promising results for the use of zebrafi sh in behavioral tests (Bretaud et al. 2007 ).
The Zebrafi sh as a Model System in Neurobiological Research
Researchers have used the zebrafi sh to analyze the biological effects of several drugs of abuse, such as ethanol (Dlugos and Rabin 2003; Gerlai et al. 2000) and cocaine (Darland and Dowling 2001) , and the reported results were similar to those found in mice. Anichtchik and colleagues (2004) have shown that catecholaminergic neurotoxins produce neurochemical and behavioral changes in the zebrafi sh, so it may be a useful model for a novel approach to analyze the effects of dopaminergic drugs as well as to identify genes involved in neurotoxicity. In addition, given that lower histamine levels in the zebrafi sh brain may be related to impairment in memory and learning, this model is appropriate for assessments of higher cognitive processes (Peitsaro et al. 2003) . The zebrafi sh also represents an alternative model to study some locomotor disorders (Flinn et al. 2008 ).
As mentioned above, the zebrafi sh offers the possibility of performing high-throughput phenotype-based screens, both genetic (Haffter et al. 1996) and small-molecule screens (reviewed in Pichler et al. 2003; Zon and Peterson 2005) , thus enabling preclinical tests in vivo as well as studies of the neurobiological effects of various drugs of abuse. In fact, some groups have described the use of zebrafi sh to study the mechanisms of dependence and the reinforcing properties of opiate drugs (Lau et al. 2006; Ninkovic and Bally-Cuif 2006) , and have even been successful when using classical behavioral tests such as the T-maze (Guo 2004) .
Finally, postulation of the zebrafi sh as a model system both to study pain and to test analgesic drugs depends on the capacity of fi sh to feel pain. In a study using the rainbow trout (Oncorhynchus mykiss), fi sh treated with noxious stimuli displayed specifi c behaviors that were not mere refl exes but rather equivalent to those observed in mammals in response to painful stimuli (Sneddon et al. 2003 ). The study also described the analgesic effect of morphine in fi sh. (For further discussions of pain in fi sh, see Sneddon 2009 and Volpato 2009 in this issue.) Opioid Agents and Pain: New Insights from the Zebrafi sh
Opiates and the Pharmacological Treatment of Pain
Morphine and its opiate derivatives are the drugs of choice for alleviating chronic pain. Soon after the extraction of morphine from opium (in the early 1800s), it gained use as both an anesthetic and an analgesic. However, it quickly became apparent that morphine was as addictive as opium, and so the search began for analgesic agents without addictive properties (for a review of the history of opium and morphine, Brownstein 1993; Snyder 1996; www.opioids.com) .
There is a wide variety of opiates, classifi ed according to their origin and/or structure. The main natural opiates are morphine, phenanthrenic alkaloids similar to morphine (codeine and thebaine), and benzylisoquinolinic alkaloids (noscapine and papaverine). Semisynthetic opiates (heroin, hydrocodone, meperidine, oxycodone, buprenorphine, and etorphine) have a morphine-like structure, whereas fully synthetic opiates (methadone, fentanyl, tramadol, metazocine, and pentazocine) display a wide range of unrelated structures that show similar pharmacological properties.
Unfortunately, opiates present some undesirable side effects, such as tolerance, dependence, and addiction (Nestler et al. 1993) . Thus there is a need for novel analgesic drugs that do not have these adverse side effects, especially in light of the widespread abuse of opiates.
Milestones and New Challenges in Opioid Research
In 1973, three research groups simultaneously demonstrated the existence of specifi c binding sites for opiates in the central nervous system of mammals (Pert and Snyder 1973; Simon et al. 1973; Terenius 1973) , thus introducing the concept of opioid receptor. Two years later, researchers isolated and identifi ed the fi rst endogenous ligands for this receptor, the enkephalins (Hughes 1975; Hughes et al. 1975) . The 1980s saw the cloning of the precursors of the opioid peptides (proenkephalin, proopiomelanocortin, and prodynorphin) 2 ; the cloning and characterization of the opioid receptors μ, δ, κ, and the ORL1 receptor followed in the next decade.
After establishing the pharmacological profi les of these opioid receptors, investigators studied the post-transductional mechanisms, such as the receptor internalization and desensitization. Later, interest focused on the intracellular effectors that mediate the activation of signalling cascades. It has been suggested that these post-transductional mechanisms are closely linked to the development of tolerance of and dependence on opiate drugs, mainly through the same plasticity mechanisms that produce adaptive changes in neural circuitries, for example, in memory and learning (Evans 2004) .
After more than 30 years of intense research on opiates, scientists now partly understand their mechanisms of action on receptors. But some fundamental questions, concerning the biochemical, cellular, and physiological processes responsible for the addictive behavior and for the induction of chronic pain, remain unanswered. The biochemical maze that occurs when an opioid agonist binds to its corresponding receptor and triggers a complex cascade of intracellular mechanisms relates directly to the diffi culty of designing new, nonaddictive analgesic drugs. Answers to these questions will require further study of the biochemical mechanisms responsible for the action of opioid drugs. But studies using classical models have not particularly advanced knowledge in this area. Given the increasing use of the zebrafi sh as a novel model in neuropharmacology, characterization of the opioid system in this animal can shed new light on the mechanisms that mediate opioid activity.
The Endogenous Opioid System in the Zebrafi sh: Structure, Molecular Biology, Expression, and Pharmacology
Zebrafi sh Opioid Receptors
In view of the fundamental role of the opioid system in pain control, the study of the zebrafi sh opioid system may play an essential role in furthering understanding. Four opioid receptors have been cloned in the zebrafi sh (dr 1 in the abbreviations below):
opioid receptor (drDOR1 1 ; previously ZFOR1; database access number AJ001596 or NM_131258), which displays a high degree of similarity to the mammalian δ opioid receptor (Barrallo et al. 1998a,b) ; drDOR2 (previously ZFOR4; database access number • NM_212755 or AY262256), a drDOR1 duplicate that shows high sequence similarity to other δ receptors (PinalSeoane et al. 2006) ; the • μ opioid receptor homologue drMOR 1 (previously ZFOR2; database access number NM_131707 or AF132813) ; and drKOR • 1 (previously ZFOR3; database access number NM_182886 or AF285173), homologous to the mammalian κ opioid receptor ).
The hydrophobicity analysis of these proteins indicates the existence of seven transmembrane domains, and these receptors are members of the G protein-coupled receptor (GPCR) superfamily.
The expression pattern of these four opioid receptors has been analyzed in the adult zebrafi sh brain using hybridization Pinal-Seoane et al. 2006; Porteros et al. 1999 ; results are summarized in Table 1 ). In general, the opioid receptors show a wide pattern of distribution in the zebrafi sh brain, with the most intense labeling in regions involved in sensory information processing and in areas that are part of the analgesic pathways.
Pharmacological Profi le of Opioid-Binding Sites in Zebrafi sh Brain Homogenates
The pharmacological profi le of opioid-binding sites in zebrafi sh brain homogenates has been studied using radioactive binding techniques . The nonselective antagonist [ 3 H]-diprenorphine shows high 
drDOR1
The functional characterization of the zebrafi sh opioid receptors has been carried out using prototypical opioid ligands  (Table 2 ) typical of agonists (Capeyrou et al. 1997) . However, none of the peptidic ligands displace 100%, whereas the nonpeptidic agents displace all bound [ 3 H]-diprenorphine. Selective ligands for the δ receptor (DPDPE) and κ receptor (U69,593) fail to show an effective displacement, thus confi rming the μ selectivity of drMOR. Etorphine shows the highest affi nity for drMOR, whereas endomorphin-2, CTOP, 6 and PLO17 present the lowest affi nities. As expected, neither naloxone nor the μ-specifi c antagonist CTOP activates drMOR, as determined in [ 35 S]GTPγS assays. Surprisingly, naltrindol, a d-selective antagonist, behaves as an inverse agonist on drMOR (Marron et al. 2009 ). This result is in accordance with the fi nding that some ligands, such as TIPP (H-Tyr-Tic-Phe-Phe-OH), behave as agonists, antagonists, or inverse agonists depending on the assay conditions and the signalling pathways under study (Martin et al. 2002) .
, but the selective agonist for mammalian κ receptors, U69,593, does not bind to drKOR ( The conclusion from these pharmacological studies is that nonselective opioid ligands bind both the mammalian and the zebrafi sh opioid receptors in a similar fashion; however, the zebrafi sh receptors display reduced affi nity for the highly selective opioid agents with proven activity on their mammalian counterparts. These results suggest that the binding pocket of the opioid receptors is highly conserved throughout evolution, whereas the extracellular domains that confer ligand selectivity are less conserved (Gonzalez-Nunez et al. 2007b ).
Zebrafi sh Opioid Peptides
Characterization of zebrafi sh opioid receptors permitted examination of their endogenous ligands and then the cloning and characterization of the opioid precursors, which revealed the following: The opioid peptides encoded by these precursors can be classifi ed as (1) peptides that are present in both zebrafi sh and mammals, (2) zebrafi sh peptides with a homologue in mammals, and (3) new peptidic sequences specifi c to the zebrafi sh. Whatever their classifi cation, these novel opioid peptides represent new tools to study the complex interactions between a receptor and its corresponding ligand.
drPENK
Zebrafi sh PENK codes for a polypeptide of 249 residues with the consensus sequences for four Met-enkephalins (ME), one Leu-enkephalin (LE), and one Met-enkephalinGly-Tyr (MEGY 1 ) (Figure 1 ; Gonzalez-Nunez et al. 2003a) . The MEGY heptapeptide is present in two different evolutionary lineages of fi sh (actinopterigian and sarcopterigian fi sh), which share a common ancestor with tetrapods; thus this peptide appeared early in evolution and later evolved to Met-enkephalin-Arg-Phe (MERF) in tetrapods (GonzalezNunez et al. 2003a ).
Another sequence with high homology with proenkephalins, drPENK-like, was also identifi ed and represents a duplicate proenkephalin gene, with the consensus sequences for four Met-enkephalins, one Met-enkephalin-Ile, and one Met-enkephalin-Asp (Figure 1 ; Gonzalez-Nunez et al. 2003a ). This was the fi rst time that two endogenous opioid hexapeptides were described, and it is possible that they have novel functions that are not present in mammals, as is true of other genes in the zebrafi sh (Meyer and Schartl 1999; Sidow 1996) .
To analyze the pharmacological profi le of MEGY, its tritiated derivative ([ 3 H]-MEGY) was obtained and used in radioligand binding assays on zebrafi sh and rat brain homogenates (Gonzalez-Nunez et al. 2005) . We found that [ 3 H]-MEGY presents a single binding site in both zebrafi sh and rat brain membranes, with similar affi nities (K D = 2.4 nM and 3.8 nM, respectively). Competition binding experiments have revealed that Met 5 is essential for high affi nity binding of peptides to opioid receptors. In addition, an examination of the binding profi le of MEGY on isolated δ receptors from zebrafi sh, drDOR1 and drDOR2 (GonzalezNunez et al. 2007b) , showed that drDOR1 presents a single binding site for MEGY peptide and other ligands, using both δ receptors from zebrafi sh. When [ 3 H]-MEGY was used as radioligand, the experimental K i values were in the nanomolar range, and when [ 3 H]-diprenorphine was used these affi nities dropped by two orders of magnitude (Table 2 ). The differences in the resulting K i values can be explained by assuming that agonists and antagonists bind differentially to these receptors (Gonzalez-Nunez et al. 2007b) .
Functional studies have established that both drDOR1 and drDOR2 are functional receptors that can be activated by endogenous ligands (MEGY, ME, LE) as well as by synthetic agonists (BW373U86) ( Table 2 ). Thus MEGY is one of the endogenous ligands of the two δ opioid receptors from zebrafi sh drDOR1 and drDOR2 (Gonzalez-Nunez et al. 2007b) .
drPOMC
Zebrafi sh POMC encodes a polypeptide of 222 residues with the consensus sequences for the adrenocorticotropin hormone (ACTH), γ-lipotropin (γ-LPH), β-melanotropin (β-MSH), and the opioid peptide β-endorphin (β-END) ( Figure  1 ; Gonzalez-Nunez et al. 2003c) . Studies show that drPOMC is selectively expressed in the nervous tissue and in the pituitary in adult fi sh (Gonzalez-Nunez et al. 2003c) . As in the case of drPENK, another duplicate gene for drPOMC was found, drPOMC-like, which displays a more degenerate sequence (Figure 1) , in which only β-endorphin and α-melanotropin can be considered end products, since the other peptides have lost the consensus sequences for proteolytic processing (Gonzalez-Nunez et al. 2003c ).
drPDYN
The complete open reading frame of zebrafi sh PDYN codes for a polypeptide of 252 amino acids with the consensus sequences for four opioid peptides: Ile-enkephalin, the neoendorphins, dynorphin A (DYN A), and dynorphin B (Figure 1 (Table 2 ; Gonzalez-Nunez et al. 2007a ). This comparative study indicates that mammalian and zebrafi sh opioid receptors bind their corresponding dynorphin A in a similar fashion and are thus homologous systems (GonzalezNunez et al. 2007a) .
drPNOC
Zebrafi sh PNOC propeptide contains 233 residues and displays the consensus sequences for two nociceptin peptides (Figure 1 ), while mammalian PNOCs code for only one nociceptin (Gonzalez-Nunez et al. 2003b) . One of these nociceptins, drNOC-like, is 22 amino acids long, displays 47% identity to mammalian nociceptin, and contains the N-terminal consensus sequence "Phe-Gly-Gly-Phe". The other peptide, drNOC, displays 70% identity with the mammalian NOC, although its N-terminus sequence ("Tyr-Gly-GlyPhe", an enkephalin sequence instead of a NOC sequence) resembles DYN A more than the mammalian nociceptin (Gonzalez-Nunez et al. 2003b) . Following the "messageaddress" theory (Meunier et al. 1995) , the "message" of nociceptin is made by "Phe 1 -Gly 2 -Gly 3 -Phe 4 ", where Phe 1 can be substituted by Tyr without major changes in the activity; the "address" of nociceptin must contain basic residues (Arg 8 -Lys 9 and Arg 12 -Lys 13 ), where Arg 8 must always be present; the C-terminus must also be conserved. The two drNOCs display the common features of the "message" and "address" domains, meaning that these two peptides may act as full agonists on the ORL receptor. In addition, Tyr 1 is a key residue for the binding of endogenous peptides to opioid receptors, and the synthetic ligand Tyr-nociceptin binds not only to ORL with high affi nity but also to κ and μ opioid receptors (Lapalu et al. 1997; Reinscheid et al. 1996) . Therefore it is possible that drORL binds nociceptin as well as opioid peptides, and/or that drNOC binds to opioid receptors, especially the κ type (Gonzalez-Nunez et al. 2003b ).
Linking Opioid Receptors and Development: A View from the Zebrafi sh
As mentioned above, the zebrafi sh has been extensively used in developmental studies as well as to shed light on the pathological mechanisms of certain diseases. The capacity of the zebrafi sh to mimic human pathological processes has facilitated discovery of the endogenous pathways leading to those processes. Both research fi elds, development and disease, are interconnected, as many alterations of physiological mechanisms found in adults are initiated during embryogenesis, as a consequence of a mutation or exposure to an agent that interferes with the correct development of the embryo (Shin and Fishman 2002) . Cloned zebrafi sh opioid receptors and peptides display a high degree of similarity to their mammalian counterparts and are therefore useful in both types of studies. But there are subtle differences that may affect the actions of opioid receptors during development, and interactions between the receptors could be involved not only in embryogenesis but also in the development of the adult nociceptive system.
Quantitative Expression Analysis of Opioid Receptors during Zebrafi sh Embryonic Development
A recent study investigated the expression of the μ, δ, and κ opioid receptors in zebrafi sh embryos at different developmental stages from 0.5 hpf to 72 hpf by quantitative polymerase chain reaction (PCR) and in situ hybridization (Sanchez-Simon and Rodríguez 2008) . For real-time PCR experiments, total RNA was extracted from 300 embryo batches at each developmental stage using TRIzol ® reagent. cDNA was then synthesized by reverse transcription and the different opioid receptors were amplifi ed on these cDNAs and quantifi ed by means of the SYBR-green reagent. A standard curve was established for each opioid receptor, amplifying the receptors on the purifi ed product of each receptor using 1:10 dilutions of a known concentration. The number of copies is referred to 25 ng of cDNA from 300 embryo batches, as the reverse transcription PCR (RT-PCR) experiments were done in two steps.
The studies established that each opioid receptor shows a different expression profi le during zebrafi sh development. mRNA transcripts for each opioid receptor were detectable with real-time PCR as early as 30 minutes after fertilization. Since it is not until 2.75 hpf that the mRNA begins to be synthesized by the embryo itself (midblastula transition; Newport and Kirschner 1982) , the opioid receptor transcripts in younger embryos are considered maternal. The fl uctuations in the levels of opioid receptor transcripts are not the result of experimental degradation of the mRNA, since β-actin exhibited a constant expression level throughout the zebrafi sh embryonic development.
A summary of these expression studies is presented in Figure 2 . The two δ opioid receptors from zebrafi sh present different expression profi les but both have an expression peak at 22 hpf. However, at this particular stage, the number of drDOR2 transcripts almost triples that of drDOR1. The expression levels of drDOR1 decrease from a maximal expression level at 22 hpf until 48 hpf, when 10 6 copies of transcript per 25 ng cDNA are observed. As in the drMOR expression profi le, the number of drDOR1 transcripts decreases at 60 hpf and increases toward the end of the embryonic developmental period, at 72 hpf. In contrast, the expression of drDOR2 reaches its maximum at 22 hpf and then declines without any increase in expression until the end of the period of observation. Considering these data, drDOR2 expression was analyzed in further detail at this particular stage, from 19 hpf to 24 hpf: the expression levels start to increase at 20 hpf, peak and plateau at 21 hpf, and begin to decrease at 23 or 24 hpf. At 19 hpf, the embryo begins to have spontaneous tail movements and at 21 hpf this movement is associated with a refl ex (Saint-Amant and Drapeau 1998). Both δ duplicates are expressed at lower levels in the zebrafi sh adult brain than during the last stage of development, a feature shared with the µ opioid receptor.
The expression of drMOR increases at 3 hpf as a result of the accumulation of maternal and embryonic transcripts. The mRNA copies then decrease until 16 hpf, when their expression progressively increases until 22 hpf, within the segmentation period (10.75 hpf to 24 hpf; Kimmel et al. 1995) . Lower expression of drMOR is observed between 22 hpf and 48 hpf, when the highest peak of receptor expression is detected, over 8 × 10 5 copies of receptor transcripts per 25 ng cDNA. This is a sevenfold increase compared to previous stages. The number of transcripts decreases at 60 hpf and increases again at the transition from embryonic to larval development (i.e., at 72 hpf). Finally, drMOR expression in the adult brain (~4.51 × 10 5 copies per 25 ng cDNA) is signifi cantly lower than at certain developmental stages (i.e., at 48 or 72 hpf).
drKOR exhibits a different expression profi le from the other three opioid receptors: while drDOR and drMOR display 10 5 to 10 6 transcript copies per 25 ng cDNA, drKOR expression is very low, its highest level equal to 1500 copies per 25 ng of cDNA at 48 hpf. The expression then decreases until the end of the embryogenesis, without any further increase, as is true of the expression profi le of drMOR and drDOR1. Also, in contrast to what was observed for other opioid receptors, the number of drKOR transcripts is higher in the zebrafi sh adult brain than during embryonic development.
Expression Pattern of Opioid Receptors during Zebrafi sh Embryonic Development
The expression pattern of these four opioid receptors was determined by in situ hybridization (data not shown). drMOR mRNA is widely expressed in the central nervous system at 24 hpf. At this stage, differential expression of drMOR is evident in the telencephalon, epiphysis, diencephalon, midbrain, pretectum, isthmus, cerebellum, and hindbrain. Such distribution is shared by drDOR2, which is also present in myotomes and the spinal cord. drDOR2 spatial expression was also determined between 19 hpf and 24 hpf, the highest expression peak for this receptor during development. At this stage drDOR2 is present in the four encephalic subdivisions and in the tail muscle, which is the only muscle fully developed at these stages of embryonic development. Although both δ duplicates share a high degree of homology at a molecular level, their spatiotemporal distributions are different. drDOR1 is found only in the telencephalon, epiphysis, pretectum, and cerebellum, regions where drMOR and drDOR2 are also expressed. drKOR expression cannot be detected by in situ hybridization, due to its relatively low expression levels, as determined by RT-PCR. In 48 hpf embryos, drMOR is present in the tegmentum, hypophysis, otic vesicle, and pectoral fl ipper, a vital organ that develops at this stage. drMOR and drDOR1 are expressed in the tegmentum, an important group of nuclei involved in the transmission of nociceptive sensibility, and are also observed in the hypophysis, a major structure of the neuroendocrine system. However, drDOR1 is not expressed in the otic vesicle or in the pectoral fl ipper but detected in the ventral thalamus instead. In contrast, drDOR2 localization is not as defi ned as the other two opioid receptors and is detected only in the telencephalon, diencephalon, and midbrain as well as in the swim bladder, which is an important organ for the hatched embryo.
The results of the complete developmental study of the expression of opioid receptors from egg fertilization to the last stage of embryonic development suggest that zebrafi sh opioid receptors are involved in development, supporting previous works on the implication of opioid receptors in developmental processes such as neurogenesis, neuroprotection, and neuronal differentiation. Abnormalities in the transmission of the nociceptive signals or the existence of endogenous analgesia may be a consequence of a change in the endogenous opioid system during development. The study of the embryonic opioid system thus provides important information that may help in the development of new drugs for pain relief.
Conclusions
The data described here indicate that the activity of the endogenous zebrafi sh opioid system does not differ significantly from that of the mammalian opioid system. Hence, the study of zebrafi sh opioid activity may contribute to a better understanding of endogenous opioid systems in higher vertebrates. Specifi cally, the zebrafi sh can be a useful model to unravel the mechanisms that control pain and mediate analgesia, as well as to analyze the biochemical changes responsible for the development of tolerance and dependence. Given that the zebrafi sh and the mammalian opioid systems are extraordinarily similar both pharmacologically and biochemically, it is possible to perform in vivo analysis using the zebrafi sh and then extrapolate the results to higher vertebrates. Therefore, the zebrafi sh can be a highly valuable tool to design novel analgesic drugs free of the undesirable side effects of currently used analgesics.
